Aim: The implications of incidental hypoglycaemia during 75g oral glucose tolerance test in pregnant women affects the maternal and fetal outcomes is unclear.

Materials and Methods: We conducted a retrospective analysis of the 1663 women who underwent 75g 2 hour OGTT at 24-28 weeks of gestation between January 2015 to December 2017. Post-prandial hypoglycaemia was defined as blood sugar levels less than 4mmol/L. Sub-optimal birth weight was defined as birth weight less than 3000g. Parametric and non-parametric tests were used to compare baseline characteristics of those with and without post-prandial hypoglycaemia. Linear regression analysis was used to identify independent predictors of birth weight.

Results: Of the 1663 patients, 178 (10.7%) had GDM. In patients without GDM 126 (8%) had post-prandial hypoglycaemia. There were no significant differences in baseline anthropometric and clinical characteristics of those with and without post-prandial hypoglycaemia. After adjustments for age (p=0.003), gestational age at delivery (p<0.0001), ethnicity (p-value<00001), fasting glucose (p<0.0001), and smoking (p-value<0.0001), post-prandial hypoglycaemia was associated with lower birth weight (beta=-106.5, p value=0.01). After adjustment for the above covariates post-prandial hypoglycaemia was significantly associated with suboptimal-birth weight (OR=1.99(CI 1.5-2.4)p-value=0.005). There were no significant differences in APGAR score at 1 and 5 minute (9.63 vs. 9.70 p-value=0.28 at 5 minutes), mode of delivery, bleeding complications during delivery (p=0.8) and neonatal admission to critical care (p=0.8) in those with post-prandial hypoglycaemia as compared to those without it.

Conclusion: Incidental post-prandial hypoglycaemia during the OGTT is associated with suboptimal birth weight and these pregnant women need close follow-up to monitor fetal growth.

Disclosure

N. Pothina: Speaker's Bureau; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Sanofi. H. Deshmukh: None. M. Panikkar: None. M. Mohammed: None. T. Sathyapalan: Speaker's Bureau; Self; Novo Nordisk Foundation. Other Relationship; Self; Bristol-Myers Squibb Company, Eli Lilly and Company, Sanofi-Aventis.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.